Biopharma Dealmakers
Издатель: Springer Nature · ISSN 2730-6275,2730-6283 · 8 статей
-
Saudi Arabia’s bold biotech plan
Biopharma Dealmakers, Published online: 15 January 2026; doi:10.1038/d43747-025-00130-1 Saudi Arabia targets global biotech leadership by 2040 with a four-pillar strategy.
-
A standardization engine for advancing cell and gene therapy manufacturing
Biopharma Dealmakers, Published online: 06 January 2026; doi:10.1038/d43747-026-00002-2 Xcell Therapeutics is developing completely animal-origin-free, chemically defined stem-cell media, enhancing safety, quality, and reproducibility.
-
SPIMACO celebrates 40 years of innovation and excellence in biopharma
Biopharma Dealmakers, Published online: 24 December 2025; doi:10.1038/d43747-025-00132-z The Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has been manufacturing and distributing high-quality therapeutics...
-
The year of the bispecific in oncology and beyond
Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00111-4 Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing...
-
Biotech trends driving the deals of 2025
Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00113-2 This year’s drug development has been characterized by multiple deals signed with companies from China, along with collaborations involving firms...
-
Innovative mRNA therapeutics based on next-generation cap analogs
Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00106-1 ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced...
-
Transforming drug discovery with generative AI
Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00099-x Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of...
-
Allogene Therapeutics: redefining the future of CAR-T
Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00108-z The biotech is aiming to develop a first-line consolidation treatment for large B-cell lymphoma that predicts and prevents relapse.